Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
Emnar Pharma Private Limited, is an unlisted private company incorporated on 23 September, 2002. It is classified as a private limited company and is located in Hyderabad, Telangana. It's authorized share capital is INR 20.00 cr and the total paid-up capital is INR 19.87 cr.
Emnar Pharma's operating revenue range is INR 100 cr - 500 cr for the financial year ending on 31 March, 2023. It's EBITDA has decreased by 3.23% over the previous year. At the same time, it's book networth has increased by 8.5%.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2023 numbers.
13.35%
-3.23%
-6.78%
8.5%
-16.81%
3.47%
-5.02
-2.2
-1.06
-1.29
-0.71
-0.22
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(6)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
CitiBank N.A.
No. of Loans: 1
Total Amount : 60.0 cr
State Bank of India
No. of Loans: 1
Total Amount : 10.3 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Sudha Mundla
Shareholder
|
00054013 | 22 years |
| Director | Vamshidhar Reddy Kallem
Shareholder
|
01133873 | 11 years |
| Director | Mundla Maha Vishnu
Shareholder
|
02470664 | 13 years |
| Director | Venkatarami Reddy
Shareholder
|
07269933 | 9 years |
| CS | Monika Sharma | <HIDDEN> | 7 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| ANDHRA ORGANICS LIMITED |
Active
|
4.5 Cr | 2 | Telangana |
| VIRCHOW LABORATORIES LIMITED |
Active
|
75.0 L | 2 | Telangana |
| VIRCHOW PETROCHEMICAL PRIVATE LIMITED |
Active
|
2.8 Cr | 3 | Telangana |
| VIRCHOW DRUGS LIMITED |
Active
|
12.2 Cr | 1 | Telangana |
| EMMENNAR CHEM PRIVATE LIMITED |
Amalgamated
|
5.0 Cr | 2 | Telangana |
| MAGNATAR AERO SYSTEMS PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| SIRI DRUGS INDIA PRIVATE LIMITED |
Amalgamated
|
7.3 Cr | 1 | Andhra Pradesh |
| SV REAL HOLDINGS PRIVATE LIMITED |
Active
|
3.4 Cr | 1 | Telangana |
| SYNAC PHARMACEUTICALS PRIVATE LIMITED |
Active
|
14.4 L | 1 | Telangana |
| ALITHIA PHARMACEUTICALS PRIVATE LIMITED |
Active
|
14.4 L | 1 | Telangana |
| AARNA & AKSHAJ INDUSTRIES PRIVATE LIMITED |
Active
|
1.0 L | 1 | Telangana |
| PISTA MOTOR RACEWAY LLP |
Active
|
1.0 L | 1 | Telangana |
| SARACA LABORATORIES LIMITED |
Active
|
8.0 Cr | 1 | Telangana |
| COVALENT LABORATORIES PRIVATE LIMITED |
Active
|
6.0 Cr | 1 | Telangana |
| AZICO PHARMACEUTICALS PRIVATE LIMITED |
Active
|
14.4 L | 1 | Telangana |
The incorporation date of EMNAR PHARMA PRIVATE LIMITED is 23 September, 2002
The authorized share capital of EMNAR PHARMA PRIVATE LIMITED is INR ₹ 20.0 Cr.
The paid-up capital of EMNAR PHARMA PRIVATE LIMITED is INR ₹ 19.9 Cr.
The registered address of EMNAR PHARMA PRIVATE LIMITED is PLOT NO: A - 4, MCH NO: 7 - 2 - A4, INDUSTRIAL ESTATE, OPP :SANATH NAGAR POLICE STATION, NA SANATH NAGAR HYDERABAD Hyderabad Telangana - 500018
The CIN number of EMNAR PHARMA PRIVATE LIMITED is U24299TG2002PTC039653.
Expand
Delete
Collapse
See
details
